Mathieu C, et al. - This trial examined if beta-cell function (as measured by HOMA2-%B) at baseline influenced the glycemic response to dulaglutide. Dulaglutide?treated subjects were enrolled from the AWARD-1, AWARD-3 and AWARD-6 clinical studies. Findings revealed greater decreases in fasting blood glucose and greater increases in fasting C-peptide in the low tertile. Similar increases in HOMA2-%B were seen in all tertiles. Regardless of estimated baseline beta-cell function, results showed clinically relevant HbA1c reduction due to dulaglutide.